Vimy Pharma was founded in 2024 by 2 former executives of Novo Nordisk
Mar 08, 2026
A newly-formed Canadian pharmaceutical company is vying to break into the market with a generic version of one of the most well-known prescription drugs in the world: Ozempic.
“You could say we’re betting everything on this one drug,” said David Suchon, co-founder of Toronto-based Vimy Pharma.
The company’s endeavour highlights domestic pharmaceutical manufacturing capabilities at a time of geopolitical uncertainties and tariff turmoil.
The data protection on semaglutide, the active ingredient in weight-loss drugs Ozempic and Wegovy, expired in January, according to Health Canada. That has opened the door for generics, which are cheaper than brand-name drugs, to enter the market.
Read more: https://www.cbc.ca/news/canada/edmonton/canada-semaglutide-company-9.7118154